Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To assess the pharmacokinetics of simvastatin and simvastatin acid with/without concomitant administration of telmisartan
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Telmisartan combined with Simvastatin | Experimental | Telmisartan once daily (day 1 to day 6) and Simvastatin given once (day 6) |
|
| Simvastatin and telmisartan placebo | Active Comparator | Telmisartan placebo once daily (day 1 to day 6) and Simvastatin given once (day 6) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Telmisartan | Drug |
| ||
| Simvastatin |
| Measure | Description | Time Frame |
|---|---|---|
| Area under the concentration-time curve of simvastatin and simvastatin acid in plasma at different time points (AUC) | Pre-dose, up to day 32 after start of treatment | |
| Maximum concentration of simvastatin and simvastatin acid in plasma (Cmax) | Pre-dose, up to day 32 after start of treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Time to Cmax after a single extravascular dose (tmax) | Pre-dose, up to day 32 after start of treatment | |
| Elimination half-life in plasma (t1/2) | Pre-dose, up to day 32 after start of treatment | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
For female subjects:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Telmisartan placebo | Drug |
|
| Total clearance from plasma (CLtot/f) |
| Pre-dose, up to day 32 after start of treatment |
| Mean time of residence in the body (MRTtot) | Pre-dose, up to day 32 after start of treatment |
| Apparent volume of distribution during the terminal phase (Vz/f) | Pre-dose, up to day 32 after start of treatment |
| Area under the plasma concentration-time curve of telmisartan at steady state (AUCss) | Pre-dose, up to day 32 after start of treatment |
| Maximum concentration of telmisartan in plasma at steady state (Cmax,ss) | Pre-dose, up to day 32 after start of treatment |
| Number of patients with clinically relevant findings in laboratory values | Pre-dose, up to day 32 after start of treatment |
| Number of patients with clinically relevant findings in vital signs (blood pressure, pulse rate) | Pre-dose, up to day 32 after start of treatment |
| Number of patients with adverse events | Up to day 32 after start of treatment |
| Number of patients with clinically relevant findings in ECG | Pre-dose, up to day 32 after start of treatment |
| ID | Term |
|---|---|
| D000077333 | Telmisartan |
| D019821 | Simvastatin |
| ID | Term |
|---|---|
| D001713 | Biphenyl Compounds |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D001562 | Benzimidazoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D008148 | Lovastatin |
| D009281 | Naphthalenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D011083 | Polycyclic Compounds |
Not provided
Not provided